EUVIMEDEUVIMED entdecken
Crossref

Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups

Benjamin N Rome iD, Aaron S Kesselheim

Arthritis & Rheumatology · 2023

DOI: 10.1002/art.42520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Benjamin N Rome und 1 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Hiccup, Antirheumatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Arnold Ventures.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsHiccupAntirheumatic AgentsHumansAdalimumabDouble-Blind Method

Substanzen

AdalimumabBiosimilar PharmaceuticalsAntirheumatic Agents

Autor:innen und Institutionen

  • Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

ORCID-Profile: Benjamin N Rome

Förderung

  • Arnold Ventures

Zitieren

APA

Rome, B. N., & Kesselheim, A. S. (2023). Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups. Arthritis & Rheumatology. https://doi.org/10.1002/art.42520

Vancouver

Rome BN, Kesselheim AS. Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups. Arthritis & Rheumatology. 2023. doi:10.1002/art.42520

BibTeX
@article{Rome2023,
  author = {Rome, Benjamin N and Kesselheim, Aaron S},
  title = {Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  doi = {10.1002/art.42520}
}
Kostenlos starten →